We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$215M
1-Year Est. Return
53.68%
This Fund
S&P 500
This Quarter
Est. Return
+5.59%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$169M
AUM Growth
-$13M
(-7.2%)
Cap. Flow
-$17.8M
Cap. Flow
% of AUM
-10.58%
Top 10 Holdings %
Top 10 Hldgs %
6.26%
Holding
495
New
55
Increased
122
Reduced
257
Closed
60
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$947K |
| 2 |
Moderna
MRNA
|
+$899K |
| 3 |
Meta Platforms (Facebook)
META
|
+$895K |
| 4 |
Netflix
NFLX
|
+$876K |
| 5 |
Chipotle Mexican Grill
CMG
|
+$852K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ATVI
Activision Blizzard
ATVI
|
+$1.01M |
| 2 |
Progressive
PGR
|
+$999K |
| 3 |
Stryker
SYK
|
+$984K |
| 4 |
Republic Services
RSG
|
+$973K |
| 5 |
Linde
LIN
|
+$966K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 27.98% |
| 2 | Technology | 15.96% |
| 3 | Financials | 11.34% |
| 4 | Energy | 8.43% |
| 5 | Industrials | 8.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
151
Carlyle Secured Lending
CGBD
$698M
| $350K | 0.21% |
24,040
-566
| -2% | -$7.87K |
|
152
BridgeBio Pharma
BBIO
$16.5B
| $350K | 0.21% |
20,345
-11,903
| -37% | -$179K |
|
153
Exelixis
EXEL
$13.9B
| $350K | 0.21% |
18,297
-729
| -4% | -$14.1K |
|
154
Hercules Capital
HTGC
$2.94B
| $349K | 0.21% |
23,603
-2,773
| -11% | -$38K |
|
155
Barings BDC
BBDC
$862M
| $346K | 0.21% |
44,163
-535
| -1% | -$4.1K |
|
156
Ionis Pharmaceuticals
IONS
$9.35B
| $345K | 0.2% |
8,418
+374
| +5% | +$14.4K |
|
157
Zai Lab
ZLAB
$2.17B
| $344K | 0.2% |
12,423
+3,646
| +42% | +$119K |
|
158
Invesco Senior Income Trust
VVR
$456M
| $344K | 0.2% |
89,336
+70,596
| +377% | +$262K |
|
159
Neurocrine Biosciences
NBIX
$17.7B
| $344K | 0.2% |
3,647
+1,062
| +41% | +$104K |
|
160
Legend Biotech
LEGN
$4.3B
| $344K | 0.2% |
4,982
-956
| -16% | -$62.5K |
|
161
Amgen
AMGN
$203B
| $343K | 0.2% |
1,546
+398
| +35% | +$92.4K |
|
|
RETA
162
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $343K | 0.2% |
3,362
+488
| +17% | +$46.2K |
|
163
Theravance Biopharma
TBPH
$874M
| $342K | 0.2% |
33,009
+5,537
| +20% | +$61.1K |
|
164
PennantPark Floating Rate Capital
PFLT
$681M
| $342K | 0.2% |
32,078
+7,158
| +29% | +$76.8K |
|
|
DCPH
165
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $341K | 0.2% |
24,233
+4,840
| +25% | +$69.3K |
|
166
Acadia Pharmaceuticals
ACAD
$4.25B
| $341K | 0.2% |
14,235
-5,285
| -27% | -$117K |
|
|
APLS
167
DELISTED
Apellis Pharmaceuticals
APLS
| $340K | 0.2% |
3,730
-2,117
| -36% | -$183K |
|
168
Gilead Sciences
GILD
$161B
| $340K | 0.2% |
4,408
+921
| +26% | +$73.5K |
|
169
Ascendis Pharma A/S
ASND
$16.7B
| $339K | 0.2% |
3,802
+1,266
| +50% | +$110K |
|
170
Harmony Biosciences
HRMY
$2.04B
| $338K | 0.2% |
9,609
+4,361
| +83% | +$151K |
|
|
ITCI
171
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $338K | 0.2% |
5,336
-504
| -9% | -$31.4K |
|
172
Aurinia Pharmaceuticals
AUPH
$1.97B
| $337K | 0.2% |
34,850
-31,098
| -47% | -$323K |
|
173
United Therapeutics
UTHR
$26.3B
| $335K | 0.2% |
1,519
+406
| +36% | +$89.9K |
|
174
BioNTech
BNTX
$22.6B
| $334K | 0.2% |
3,097
+1,442
| +87% | +$162K |
|
175
Ironwood Pharmaceuticals
IRWD
$611M
| $331K | 0.2% |
31,097
+6,259
| +25% | +$67.3K |
|
Similar funds
NCM
SSA
LIWM
VFG
IAM
1M
GC
ALS
Virtus ETF Advisers's Q2 2023 Portfolio in Review
As of Q2 2023, Virtus ETF Advisers held 495 positions worth $169M, down 7.2% from $182M the previous quarter. Its ten largest holdings account for 6.3% of the portfolio.
Virtus ETF Advisers withdrew a net $17.8M in Q2 2023, closing 60 positions and reducing 257 holdings. Its most notable exit was Activision Blizzard, an estimated $1.01M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 28% of assets, up from 26% a quarter earlier, followed by Technology and Financials.
Against the trend, Virtus ETF Advisers opened a new position in NVIDIA worth $1.21M.
- Virtus ETF Advisers's largest Q2 2023 buy was NVIDIA: 28,520 shares worth $1.21M.
- Virtus ETF Advisers added most to Moderna in Q2 2023, an estimated $899K increase.
- Virtus ETF Advisers's biggest Q2 2023 reduction was Dow Inc, cutting an estimated $898K.
- Virtus ETF Advisers fully exited Activision Blizzard in Q2 2023, selling an estimated $1.01M.
- Virtus ETF Advisers's ten largest holdings make up 6.3% of its $169M portfolio in Q2 2023.
- Virtus ETF Advisers opened 55 new positions and closed 60 in Q2 2023.
- Virtus ETF Advisers's portfolio value fell 7.2% quarter-over-quarter to $169M.
Based on Virtus ETF Advisers's 13F filing for Q2 2023, filed 14 Aug 2023.